The Study On Transplantation Of Human Umbilical Cord Blood-Derived MSCs Into Hypoxic-Ischemic Brain Damage Of Neonatal Rats

BackgroundHypoxic-ischemic brain damage (HIBD) of neonate is one of the main reasons that cause children's intelligence disability, the repairable therapy to it is still a unsolved world-wide problem today. The neural stem cells derived from embryo tissue was once considered as a remedy method, but it was confined because of its abuse, lack of source, and morality. The recent documents report that bone marrow mesenchymal stem cells which is a kind of multipotential stem cells have been successfully cultivated in vitro and differentiated into bone, muscle, liver, glial cell and neuron. And the bone marrow derived MSCs transplantation has been used in many empirical studies of several diseases. Because the bone marrow derived MSCs may be contaminated by viruses and the number of MSCs and their differentiation capacity decline with the age, their therapeutic potential might be diminished. So as a seed cell in transplantation applications, it is greatly limited. Therefore, it is very necessary to search for an optimal tool for future cell-based therapeutic applications that can replace bone marrow derived MSCs and make up its defects.Many studies have indicated that human umbilical cord blood (HUCB) is rich in hematopoietie stem cell/hematopoietic progenitor cell (HSC/HPC). HSC has been successfully used in clinical variant cell transplantation, but it is still disputed that whether there is MSCs in human umbilical cord blood. Some scholars believe that...